Despite recent insights into the biology of multiple myeloma (MM) and novel treatment, the survival still remains at 3 to 4 years. ÒLipid raftÓ microdomains within the myeloma cell surface function as platforms for regulating tumor cell growth and movement in the bone marrow. My previous studies show for the first time the presence of caveolin-1 (Cav-1) a marker protein for caveolae, specialized Òlipid raftsÓ in MM cells. I will test whether these structures are essential for MM cell growth, survival, drug resistance and migration. By investigating the mechanisms whereby lipid rafts modulate these effects, the proposed studies aim to identify new treatment targets within the MM cell surface to overcome resistance to conventional therapies and patient outcome.